卡莫来珠单抗联合经动脉化疗栓塞介入治疗肝癌合并肝硬化的临床评价

IF 1.8 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2025-07-25 DOI:10.1080/1120009X.2025.2535821

Jian Chen, Mengshan Huang

{"title":"卡莫来珠单抗联合经动脉化疗栓塞介入治疗肝癌合并肝硬化的临床评价","authors":"Jian Chen, Mengshan Huang","doi":"10.1080/1120009X.2025.2535821","DOIUrl":null,"url":null,"abstract":"This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients were categorized into an observation group (OG) (n = 60, underwent camrelizumab combined with TACE interventional therapy) and a control group (CG) (n = 60, underwent camrelizumab monotherapy). The OG showed significantly higher objective response (66.67% vs. 46.67%) and disease control rates (91.67% vs. 80.00%), improved immune function (elevated CD3+, CD4+, CD4+/CD8+), better liver function (reduced TB and ALT), and reduced tumor markers (AFP, CEA) compared to the CG. One-year follow-up revealed prolonged overall survival rate and progression-free survival, along with better quality-of-life scores in the OG. These findings suggest that camrelizumab combined with TACE demonstrates definitive short-term efficacy, improved immune and liver function, better survival outcomes, and favorable safety in HCC patients with liver cirrhosis, supporting its clinical value.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis.\",\"authors\":\"Jian Chen, Mengshan Huang\",\"doi\":\"10.1080/1120009X.2025.2535821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients were categorized into an observation group (OG) (n = 60, underwent camrelizumab combined with TACE interventional therapy) and a control group (CG) (n = 60, underwent camrelizumab monotherapy). The OG showed significantly higher objective response (66.67% vs. 46.67%) and disease control rates (91.67% vs. 80.00%), improved immune function (elevated CD3+, CD4+, CD4+/CD8+), better liver function (reduced TB and ALT), and reduced tumor markers (AFP, CEA) compared to the CG. One-year follow-up revealed prolonged overall survival rate and progression-free survival, along with better quality-of-life scores in the OG. These findings suggest that camrelizumab combined with TACE demonstrates definitive short-term efficacy, improved immune and liver function, better survival outcomes, and favorable safety in HCC patients with liver cirrhosis, supporting its clinical value.\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2025.2535821\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2535821","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

本回顾性研究评估了camrelizumab联合经动脉化疗栓塞（TACE）治疗120例肝细胞癌（HCC）合并肝硬化患者的临床疗效。根据所接受的干预，将患者分为观察组（OG）（n = 60，接受camrelizumab联合TACE介入治疗）和对照组（CG）（n = 60，接受camrelizumab单药治疗）。与CG相比，OG组的客观反应（66.67%比46.67%）和疾病控制率（91.67%比80.00%）显著提高，免疫功能（CD3+、CD4+、CD4+/CD8+升高）改善，肝功能（TB和ALT降低）改善，肿瘤标志物（AFP、CEA）降低。一年的随访显示，总生存率和无进展生存期延长，OG的生活质量评分也有所提高。这些研究结果表明，camrelizumab联合TACE在HCC合并肝硬化患者中具有明确的短期疗效、改善的免疫和肝功能、更好的生存结局和良好的安全性，支持其临床价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis.

This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients were categorized into an observation group (OG) (n = 60, underwent camrelizumab combined with TACE interventional therapy) and a control group (CG) (n = 60, underwent camrelizumab monotherapy). The OG showed significantly higher objective response (66.67% vs. 46.67%) and disease control rates (91.67% vs. 80.00%), improved immune function (elevated CD3⁺, CD4⁺, CD4⁺/CD8⁺), better liver function (reduced TB and ALT), and reduced tumor markers (AFP, CEA) compared to the CG. One-year follow-up revealed prolonged overall survival rate and progression-free survival, along with better quality-of-life scores in the OG. These findings suggest that camrelizumab combined with TACE demonstrates definitive short-term efficacy, improved immune and liver function, better survival outcomes, and favorable safety in HCC patients with liver cirrhosis, supporting its clinical value.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.